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Background: Bladder cancer (BC) is one of the most aggressive malignancies of the urinary tract, with the 2 
highest lifetime treatment costs per patient of all cancers, due to the high rate of recurrences requiring 3 
continuous surveillance. An early diagnosis is essential to improve survival of BC patients. Non-invasive and 4 
sensitive molecular biomarkers are needed to improve current strategies for the detection and monitoring 5 
of BC. Previous studies suggested that elevated DNA damage levels and suboptimal nucleotide excision 6 
DNA repair (NER) may be associated with BC.  7 
Methods: In the present study, we investigated basal DNA damage and DNA repair capacity in peripheral 8 
blood mononuclear cells (PBMCs) from 146 newly diagnosed BC patients and 155 controls using a modified 9 
comet assay able to evaluate NER activity after challenging cells by benzo(a)pyrene diolepoxide (BPDE). 10 
Results: We found an association between DNA damage levels in PBMCs of BC cases and patients’ 11 
outcomes. Basal DNA damage at diagnosis was significantly increasing with tumor grades (trend test 12 
p=0.02) and risk classes (trend test p=0.02). The overall survival analysis showed that DNA damage in 13 
patients at BC diagnosis was significantly higher in subjects with a shorter survival time (HR=3.7, 95% CI 14 
1.3–10.6, p=0.02).  15 
Conclusions: Based on these data, we suggest that DNA damage levels measured in PBMCs of BC patients 16 
may potentially represent a prognostic marker associated with poor survival; further validation is needed to 17 
better stratify BC patients for clinical trials. 18 
 19 
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1. Introduction 1 
Bladder cancer (BC) is one of the most frequent cancers of the urinary tract with the highest lifetime 2 
treatment costs per patient of all cancers [1]. In Europe, BC is the fourth most common cancer in men and 3 
the eighth most common cause of cancer-specific mortality [2].  4 
Non-muscle-invasive bladder cancer (NMIBC), which represent the 75-80% of newly diagnosed BC, recurs in 5 
50 to 70% of cases and progress to muscle-invasive disease in 1-2% of them [3]. Muscle-invasive bladder 6 
cancer (MIBC) patients have a 5-year survival rate of <50% [3].  7 
Increased levels of DNA damage and ineffective repair mechanisms are the underlying molecular events in 8 
the pathogenesis of most of the life-threatening diseases like cancer and degenerative diseases. The 9 
sources of DNA damage can be either exogenous or endogenous. BC is strongly linked to occupational and 10 
environmental exposure to chemicals [4], suggesting that DNA lesions can play an important role in its 11 
onset and development.  12 
Persistent basal DNA damage may reflect higher exposure to carcinogens and/or deficient DNA repair [5]. 13 
In recent studies we evaluated DNA repair and DNA damage levels, potentially caused by occupational 14 
and/or environmental exposure, in BC patients and healthy controls. We found significantly increased 15 
frequencies of micronuclei (MN) and nuclear buds (NBUD) in BC cases compared to controls [6] and an 16 
association between the basal levels of phosphorylation of histone variant H2AX (γ-H2AX) and risk of 17 
disease recurrence or progression [7]. These data confirmed the presence of a high genetic instability in 18 
cryopreserved lymphocytes of in BC patients. In particular, in Turinetto et al. [7] we evaluated the damage 19 
connected to double strand break repair (DSBR) mechanism, which recovers complete break of the DNA 20 
double helix. This kind of breaks /damage impairs DNA replication, transcription, or distribution of the 21 
genetic material to daughter cells [8]. Similarly to this last, also nucleotide excision repair (NER) pathway 22 
alterations can drive tumor behaviour and response to treatment [9].  23 
To address the question whether DNA damage and NER capacity could be used as a prognostic factor in BC, 24 
we investigated basal DNA damage and DRC in peripheral blood mononuclear cells (PBMCs) from a cohort 25 
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of BC patients and healthy controls already described [6, 7], using a modified comet assay able to evaluate 1 
NER activity [10, 11].  2 
The comet assay is a relatively simple, sensitive, rapid and inexpensive method that has already been 3 
employed in several DNA damage/repair clinical studies [12, 13]. Several studies have shown that basal 4 
DNA damage is increased in PBMCs of patients with different types of cancer, while other studies have also 5 
exposed PBMCs from cancer patients (usually prior to any kind of therapy) to DNA-damaging agents to 6 
assess if susceptibility to DNA damage and subsequent repair capacity differs from control samples  [14]. 7 
  8 
 9 
2. Materials and Methods 10 
2.1.  Study population.  11 
The study population included newly diagnosed, previously untreated, histologically confirmed males with 12 
BC recruited in the Turin Bladder Cancer Study [15, 16]. Controls were men recruited during the same 13 
period as cases in a random fashion from patients treated at the same urology departments for non-14 
neoplastic disease or from patients treated at the medical and surgical departments for various problems 15 
(hernias, vasculopathies, diabetes, heart failure, asthma or other benign diseases). All subjects were 16 
informed and provided written informed consent according to the Helsinki declaration. None of the 17 
patients received any treatment at the time of blood sampling. The design of the study was approved by 18 
the local Ethics Committees. Details of the study population were previously described in Pardini et al. [6]. 19 
All tumors were evaluated and classified in blind by at least two urologists of our internal department. 20 
Clinical information and risk category for NMIBC were registered through the perusal of clinical records. 21 
 22 
2.2.  Isolation and storing of PBMCs.  23 
The isolation and storing of blood cells was performed as previously described [6, 7]. Briefly, PBMCs were 24 
separated from heparinized venous blood by centrifugation with FicollPaque PLUS (GE Healthcare, Milan, 25 
Italy) at 400 × g for 30 min at room temperature. After two washes in RPMI 1640 (Invitrogen, Paisley, UK), 26 
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1% FBS (Invitrogen), 25 mM EDTA (Invitrogen), PBMCs were prepared for cryopreservation. They were 1 
resuspended at 10x106 cells/ml in freezing medium (RPMI 1640, 50% FBS, 10%DMSO), aliquoted in 2 
cryovials and slowly frozen overnight at the rate of –1 °C/min in isopropyl alcohol to –80 °C (Mr Frosty 3 
containers, Nalgene, Roskilde, Denmark). Cryovials were then transferred into liquid nitrogen for long-term 4 
storage. 5 
 6 
2.3.  Aphidicolin-block NER comet assay 7 
Cryopreserved PBMCs were thawed quickly in a 37 °C water bath and suspended in 5 ml of cold medium 8 
containing 50% FBS, 49% RPMI 1640 and 1% dextrose. Treatment with aphidicolin (APC) or/and 9 
benzo[a]pyrene diol epoxide (BPDE) was performed as previously described [11]. Briefly, cells were spun 10 
down by centrifugation and treated with 2.5 µg/ml phytohaemoagglutinin (PHA) (Sigma-Aldrich Co, St 11 
Louis, MO). Twenty-four hours later samples were centrifuged and treated in the following ways: A) 2.5 12 
µg/ml APC (Sigma-Aldrich Co), 30 min at 37 °C, 5% CO2; B) 0.5 µM BPDE (NCI Chemical Carcinogen 13 
Reference Standards Repository, Midwest Research Institute, Kansas City, MO, USA), 2 h at 37 °C, 5% CO2; 14 
C) pretreatment with 2.5 µg/ml APC (30 min) followed by 0.5 µM BPDE (2 h). At the end of the treatment, 15 
cells were centrifuged and pelleted cells were processed for comet assay.  16 
The NER comet assay was performed according to the methods previously described [10], with slight 17 
modifications [11]. After treatment, cells were mixed with low-melting-point agarose (0.75%; Sigma-Aldrich 18 
Co) and layered on 85 x 100 mm GelBond films (Lonza, Basel, Switzerland). Each GelBond film comprised 19 
eight 19 x 23 mm agarose gels. The GelBond films were immersed in lysis solution (2.5 M NaCl, 0.1 mM 20 
Na2EDTA, 10 mM Tris, 1% Triton X-100, pH 10) for 1.5 hours at 4 °C, then placed in an electrophoresis tank 21 
for 40 minutes, submerged into electrophoresis buffer (0.3 M NaOH, 1 mM Na2EDTA, approximately pH 22 
13), and finally ran at 30 V (0.8 V/cm) and 300 mA for 20 min. After neutralization with 0.4 M Tris-HCl (pH 23 
7.5), gels were fixed in ethanol and dried at room temperature. For scoring, slides were stained with YOYO-24 
1 iodide (1 mM solution in DMSO, diluted 1:250 in PBS; Life Technologies Italia, Monza, Italy) and nuclei 25 
were visualized by a Leica fluorescence microscope at 40X magnification. Two gels of 50 nuclei for each 26 
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sample treatment were scored with Comet IV software (Perceptive Instrument, Suffolk, UK). The median 1 
tail moment (TM) of 100 nuclei was used as a measure of DNA damage. The TM is defined as the product of 2 
the tail length and the fraction of total DNA in the tail (Tail moment=tail length x % of DNA in the tail). TM is 3 
calculated automatically by the computer software system as an average for the 50 cells selected for 4 
measurement. For each electrophoresis run, a human K562 erythroleukemia cell line was included as 5 
reference standard and used to normalize results [11]. Since in our previous study we demonstrated that 6 
APC-treated and untreated cells did not differ in DNA damage levels [11], in this study we directly used 7 
APC-treated cells endpoint as representative of basal DNA damage. DRC (NER capacity) was calculated for 8 
each subject as: TM DNAAPC+BPDE – TM DNABPDE - TM DNAAPC.  9 
 10 
2.4.  Statistical analysis.  11 
Patient characteristics were described as absolute frequencies for qualitative variables, and with mean, 12 
standard deviation (SD) and range values for quantitative variables. The analysed variables were basal DNA 13 
damage in APC-treated cells and DRC, obtained as described above.  14 
The influence of possible explicative variables on the basal DNA damage or DRC was evaluated by 15 
multivariate analysis and/or non-parametric statistical hypothesis test, since variables did not follow a 16 
normal distribution (Shapiro–Wilk normality test).  17 
Wilcoxon or Kruskal-Wallis Rank Sum tests were applied to compare the distribution between groups of 18 
basal DNA damage or DRC.  19 
Overall survival (OS) was evaluated calculating the time (in years) between the date of BC diagnosis and the 20 
date of death or follow up termination as the endpoint for each patient. Event-free survival (EFS) was 21 
calculated as the time (in years) between the date of BC diagnosis until date of relapse, death or 22 
censorship, whichever came first. The relative risk of death or recurrence against each of the basal DNA 23 
damage or DRC endpoints was estimated as hazard ratios (HR) using Cox regression (R 3.2.4, Survival 24 
package). Basal DNA damage or DRC were all considered as categorical (above/below the median value). 25 
Multivariate survival analyses were adjusted for age, smoking, T stage and therapy variables for the whole 26 
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group of patients. The prognostic role of DNA damage or DRC on survival was also evaluated using Kaplan 1 
Meier curves and log-rank test. 2 
All the analyses were performed with the open source R (R 3.2.4). 3 
 4 
3. Results 5 
3.1. Study population. 6 
The study included PBMCs from 146 cases and 155 controls. For 61 subjects technical problems were 7 
encountered in one or more of the three points (i.e., slides were not scorable), therefore basal DNA 8 
damage or DRC were not evaluable. Since no additional aliquots of cryopreserved PBMCs were available, 9 
these subjects were excluded from the analysis. Finally, 133 BC patients and 141 control subjects were 10 
included in the basal DNA damage analysis, while 121 BC patients and 119 controls subjects were included 11 
in the DRC analysis. The characteristics of the whole cohort are summarized in Table 1. For 131 patients, 12 
tumors were classified as NMIBC, whereas 15 patients resulted MIBC at diagnosis. As current grading 13 
classifications in BC (WHO 2004/2016) are suboptimal, and as the 1973 system (WHO 1973) identifies more 14 
aggressive tumors [17], we took into consideration both classifications in the statistical analysis. Thirty-15 
eight BC cases presented grade G1 cancer, while 60 and 48 had G2 and G3 grade, respectively. Fifty-five 16 
cases were classified as high-risk, 41 as intermediate and 35 as low-risk. Fifty-two BC patients developed 17 
one or more recurrences, whereas 94 did not.  18 
 19 
3.2. Comet assay endpoints in relation to clinical outcomes.  20 
DRC was evaluated by a modified comet assay that measures the capacity of PBMCs to resolve DNA 21 
damage after in vitro challenging with BPDE in the presence or absence of APC, a potent and specific 22 
inhibitor of DNA polymerases α and σ [18]. No differences between cases and controls were observed by 23 
Wilcoxon Rank Sum test, neither considering only NMIBC or MIBC cases (Table 2). Same results were 24 
obtained with a generalized linear model, controlling for age and smoking habits. 25 
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Basal DNA damage levels and DRC correlation with grading, risk classes and recurrences were evaluated, 1 
either in all cases or NMIBC only (Table 3). Although DRC did not show any significant correlation with 2 
clinical characteristics of tumors, basal DNA damage at diagnosis was significantly different between tumor 3 
grading (all BC: WHO 1973 G3 vs G1 adjusted linear regression p=0.02; WHO 2004/2016 adjusted linear 4 
regression p=0.04, Fig 1A and 1B, respectively; NMIBC: WHO 1973 G3 vs G1 adjusted linear regression 5 
p=0.01; WHO 2004/2016 adjusted linear regression p=0.03, Supplementary Fig S1A and S1B, respectively). 6 
We also observed a significant positive trend of correlation between basal DNA damage and tumor grading 7 
(all BC: p=0.02; NMIBC: p=0.01), suggesting that DNA damage increases with invasive progression. 8 
Moreover, basal DNA damage was significantly different also between risk classes (all BC: High vs Low risk 9 
adjusted linear regression p=0.03; Fig. 1C; NMIBC: High vs Low risk adjusted linear regression p=0.02; 10 
Supplementary Fig S1C), with a significant positive trend in NMIBC with the increase of risk (p=0.02). 11 
 12 
3.3. Overall survival, recurrence rate and event-free survival analyses  13 
Results from the survival analysis are reported in Table 4 and shown in Fig. 2. Patients were stratified into 14 
two categories, above and under the median value of DNA damage or DRC, to calculate Kaplan–Meier OS 15 
curves.  16 
Values above the median value of basal DNA damage corresponded to the “High DNA damage” group, 17 
those under the median value corresponded to the “Low DNA damage” group. There was a significantly 18 
decreased survival in patients with an increased basal DNA damage level both in all BC patients and also 19 
when stratified only for NMIBC (HR=3.7, 95%CI 1.3–10.6, p=0.02 and HR=4.4, 95%CI 1.1–17.3, p=0.03, 20 
respectively). There was no association between DRC and OS, neither between EFS and both comet assay 21 
endpoints (Table 4).  22 
Patients that developed recurrences at follow-up showed a significantly lower basal DNA damage 23 
compared to patients that did not (all BC, adjusted linear regression p=0.03, Fig. 1D and Table 3; NMIBC, 24 
adjusted linear regression p=0.01, Supplementary Fig S1D). This suggests that patients having a higher basal 25 
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DNA damage probably presented an induced increased DNA repair response resulting in a lower risk of 1 
recurrences. 2 
 3 
4. Discussion 4 
In the present study, we observed a significant increased basal DNA damage in PBMCs from BC patients 5 
when stratified for grade, risk class or recurrence rate. Moreover, a lower DNA damage in patients at 6 
diagnosis was associated with longer survival time.  7 
Morphologic and pathologic criteria (e.g. histology, stage, grade) used for conventional diagnosis of BC [19] 8 
have inadequate power to predict patient outcome precisely, and there remains significant variability in the 9 
prognosis of patients with similar characteristics [20]. Thus, new biomarkers that predict clinical behaviour 10 
in patients with BC is needed especially regarding non-invasive tissues, like blood or urine [21].  11 
Elevated DNA damage levels and suboptimal NER, the major DNA repair mechanism for repairing bulky 12 
DNA damage generated by most environmental factors [22], may be associated with BC, as reported in 13 
previous studies [23, 24, 25]. We hypothesized that a quantification of the DNA damage and DRC might 14 
serve as BC risk and prognostic biomarkers. The comet assay modified method used in this study allows in 15 
fact to measure the accumulation of DNA breaks, as incision events, by blocking repair synthesis, and is 16 
adequate to detect DRC inter-individual differences in the context of NER pathway [26].  17 
In a previous study, baseline levels of DNA damage measured by a similar assay was significantly higher in 18 
BC patients than in controls [27]. The main difference with our study consisted in the type of cells: while 19 
Schabath et al [27] quantified DNA damage on fresh whole blood , we measured DNA damage on 20 
cryopreserved PBMCs. Moreover, we compared BC cases with hospitalised controls, instead of healthy 21 
subjects: this could be an issue when measuring disease markers, as the ideal control group would 22 
comprise a random sample from the general population that gave rise to the cases. However, as in our 23 
case, this is not always possible in practice. We applied in a previous study on DNA repair NER comet assay 24 
on 122 healthy subjects [26]. Unfortunately these subjects were different from BC cases both in age (mean 25 
age 24.5 years) and in gender distribution (39 males, 83 females) and could not be used as controls in the 26 
11 
 
present study. However, we observed basal DNA damage levels lower than in controls from BC study (0.022 1 
in subjects included in [26] vs 0.21 in BC study controls; data not shown). These data may explain why we 2 
could not observe a significant difference between BC cases and controls.  3 
In the present study, we found that the basal DNA damage was significantly associated with a worse patient 4 
prognosis. The DNA damage increase in PBMCs of high grade (WHO 2004/2016) or G3 (WHO 1973) BC, 5 
could be interpreted as an altered status in the DNA damage repair system or a consequence of an 6 
unknown past exposure. Tumor grade is an important predictor of cancer prognosis [28]. However, 7 
histopathological classifications are known for their inter- and intra-observer variability which may have 8 
profound limitations in prognosis [29]. Hence, basal DNA damage levels in PBMCs may serve as potential 9 
predictive biomarkers for a better stratification of BC patients. 10 
The comet assay used to measure DRC is specific for NER, but it detects a wide range of type of DNA 11 
damages at basal levels. Alkaline comet assay, in fact, is capable of detecting DNA double-strand breaks, 12 
single-strand breaks, alkali-labile sites, DNA-DNA/DNA-protein cross-linking, and incomplete excision repair 13 
sites, with no specific assignment of the DNA repair pathways responsible for that. We hypothesize that 14 
increased DNA damage in patients with worse outcome is associated with alterations in different DNA 15 
repair pathways that subsequently may lead to carcinogenesis. However, the exact mechanism explaining 16 
this phenotype remains to be elucidated. 17 
We previously observed a significant association between increased γ-H2AX basal phosphorylation level 18 
and a decreased BC recurrence risk [7]. The results suggested a protective effect of high basal DSBR 19 
signalling in terms of preventing BC recurrences. On the contrary, a more general assessment of DNA 20 
damage as determined by comet assay revealed an association between higher basal DNA damage at the 21 
time of BC diagnosis and a decreased risk of recurrences at follow-up. One possible explanation could be 22 
that DNA repair pathways are involved in tumor chemoresistance [30], decreasing therapy benefits. 23 
However, further analyses are needed to elucidate this conflicting results. The relationship between DNA 24 
damage and repair is complex; no single pathway efficiently repairs all types of DNA lesions, and some of 25 
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them are substrates for more than one pathway. Moreover, there is an increasing evidence of extensive 1 
interactions among proteins involved in distinct pathways. 2 
We are aware of some limitations of the present study. The potential use of the comet assay for DNA 3 
damage and repair activity associated with cancer was reviewed by McKenna et al. [14]. Recent studies 4 
showed that high levels of DNA damage in PBMCs were associated with different types of cancer, including 5 
breast [31, 32], cervix [33], Hodgkin's disease [34], and oesophageal cancer [35]. On the other hand, these 6 
outcomes were not observed in other type of cancer such as lung [36] and prostate [37]. Noteworthy, the 7 
observed associations between DNA damage and disease established in case–control studies do not allow 8 
to conclude whether the elevated DNA damage is a cause or a consequence of the disease. To establish 9 
causality, prospective studies need to be conducted. Finally, in our study we recruited only men affected by 10 
BC, thus we can only hypothesise that DNA damage could be a good prognostic biomarker also in BC 11 
women. Møller et al. [38] reported that gender is one of the factors that influence the level of DNA damage 12 
detected by the comet assay in biomonitoring occupational studies, confirming that further analyses should 13 
be done in female patients affected by BC. 14 
 15 
5. Conclusions 16 
We have shown an association between DNA damage levels and BC patients’ outcomes.  17 
Our data suggest that basal DNA damage levels in BC patients may potentially represent an important 18 
prognostic marker associated with poor OS and after further validation could be used for a better 19 
stratification of BC patients for therapy, decreasing progression rate and improving patients’ outcomes. 20 
Hence, reliable methods for detecting DNA damage levels in PBMCs in cancer patients may improve and 21 
amplify the diagnostic and prognostic tools. Moreover, targeting DNA damage repair pathways may 22 
contribute to improving conventional therapy regimens. 23 
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Table 1. Demographic and clinical characteristics of BC patients and healthy controls  1 
Covariates Controls (%) Cases (%) 
N 155 146 
Non-muscle invasive BC - 131 (89.7) 
Muscle invasive BC - 15 (10.3) 
Age (years)   
Mean ± SD 62.46 ± 8.63 62 ± 7.86 
Range 40.31 – 74.59 39.99 – 74.10 
Smoking Status   
Never 25 (16.1) 23 (15.8) 
Former 94 (60.7) 89 (60.9) 
Current 36 (23.2) 34 (23.3) 
T stage*   
Ta  78 (53.4) 
T1  47 (32.2) 
≥T2  15 (10.2) 
Tis  3 (2.1) 
Tx  3 (2.1) 
Grading (WHO 1973)*   
     G1  38 (26) 
G2  60 (41.1) 
G3  48 (32.9) 
Grading (WHO 2004/2016)*   
     Non-high grade  72 (49.3) 
High grade  74 (50.7) 
Risk*   
     Low-risk  35 (24) 
Intermediate Risk  41 (28.1) 
High-risk  55 (37.7) 
Muscle invasive  15 (10.2) 
Recurrences   
     No  94 (64.4) 
Yes  52 (35.6) 
Number of recurrences   
     1  31 (59.6) 
2  16 (30.8) 
≥3  5 (9.6) 
Progression   
     No  140 (95.9) 
Yes  6 (4.1) 
Therapy   
     No  43 (29.5) 
Yes  103 (70.5) 
Cystectomy   
18 
 
     No  119 (81.5) 
Yes  27 (18.5) 
BC patient’ status at follow up   
     Alive  122 (83.6) 
Died  24 (16.4) 
 1 
*For reference see Babjuk M et al, Eur Urol. 2017. 2 
  3 
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Table 2. Basal DNA damage and nucleotide excision DNA repair capacity in PBMCs from BC cases and 
healthy controls  
        
        
  
Background DNA damage 
  Controls BC p-value* NMIBC p-value* MIBC p-value* 




14   
Meana (SD) 0.21 (0.19) 0.19 (0.18) 0.64 0.19 (0.18) 0.53 0.22 (0.19) 0.66 
  
DNA Repair Capacity  
  Controls BC p-value* NMIBC p-value* MIBC p-value* 




13   
Meanb (SD) 12.28 (9.56) 14.15 (10.89) 0.21 14.01 (11.05) 0.29 15.34 (9.80) 0.25 
        a Mean of comet tail moment  
     b Mean DRC calculated as described in Materials and methods section 
   * Wilcoxon Rank Sum test 
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Table 3. Basal DNA damage and nucleotide excision DNA repair capacity in PBMCs from all BC cases or NMIBC stratified for grade, risk and recurrence rate 
            




 (mean±sd) p* adj p** 
trend 
 p*** ALL CASES 
DRC 
 (mean±sd) p* adj p** 
trend  
p*** 
 Tumor Type NMI (n=119) 0.19 ± 0.18 0.38 ref nd NMI (n=108) 14 ± 11.1 0.72 ref nd 
   MI (n=14) 0.22 ± 0.19   0.62   MI (n=13) 15.3 ± 9.8   0.99   
 Grading  G1 (n=36) 0.13 ±0.11 0.1 ref 0.02 G1 (n=33) 13.1 ±10.2 0.67 ref 0.36 
 (WHO 1973) G2 (n=51) 0.2± 0.17   0.08   G2 (n=45) 15.7± 12.1   0.81   
   G3 (n=46) 0.23 ±0.22   0.02   G3 (n=43) 13.3 ±10.1   0.36   
 Grading  Non high grade (n=65) 0.16 ±0.14 0.11 ref nd Non high grade (n=58) 14 ±11.1 0.89 ref nd 
 (WHO 2004/2016) High grade (n=68) 0.22± 0.20   0.04   High grade (n=63) 14.3 ±10.8   0.58   
 Risk Low (n=33) 0.13±0.11 0.39 ref 0.11 Low (n=30) 14.4±10.2 0.89 ref 0.55 
   Intermediate (n=36) 0.19±0.17   0.25   Intermediate (n=31) 14.1±11.9   0.6   
   High (n=50) 0.22±0.21   0.03   High (n=47) 13.7±11.2   0.26   
   MI (n=14) 0.22±0.19   0.16   MI (n=13) 15.3±9.8   0.62   
 Recurrences No (n=88) 0.21 ±0.19 0.03 ref nd No (n=80) 14.5 ±10.9 0.67 ref nd 




DNA damage  




(mean±sd) p* adj p** 
trend  
p*** 
 Grading  G1 (n=36) 0.13± 0.11 0.14 ref 0.01 G1 (n=33) 13.1± 10.2 0.69 ref 0.35 
 (WHO 1973) G2 (n=50) 0.20 ±0.17   0.09   G2 (n=44) 15.5± 12.1   0.95   
   G3 (n=33) 0.23± 0.23   0.01   G3 (n=31) 12.9± 10.5   0.35   
 Grading Non high grade (n=65) 0.16± 0.14 0.17 ref nd Non high grade (n=58) 14± 11.1 0.96 ref nd 
 (WHO 2004/2016) High grade (n=54) 0.22± 0.21   0.03   High grade (n=50) 14.1± 11.1   0.56   
 Risk Low (n=33) 0.13 ±0.11 0.34 ref 0.02 Low (n=30) 14.4 ±10.2 0.81 ref 0.25 
   Intermediate (n=36) 0.19 ±0.17   0.24   Intermediate (n=31) 14.1 ±11.9   0.57   
   High (n=50) 0.22 ±0.21   0.02   High (n=47) 13.7 ±11.2   0.25   
 Recurrences No (n=74) 0.21± 0.19 0.04 ref nd No (n=67) 14.3± 11.2 0.7 ref   
   Yes (n=45) 0.15 ±0.15   0.01#   Yes (n=41) 13.5 ±10.9   0.90#   
 
            
21 
 
            * Wilcoxon Rank Sum or Kruskal-Wallis Rank test 
         ** Generalised linear model adjusted for age and smoking habits (ref = reference group) 
     *** Trend test adjusted for age and smoking habits 
         # Generalised linear model adjusted for age, smoking habits and therapy 
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Table 4. Basal DNA damage and nucleotide excision DNA repair capacity  affecting overall survival (OS) and event free 
survival (EFS) in all BC and NMIBC. 





HR 95% CI p-value* 
 
HR 95% CI p-value* 
 DNA damage# 3.7 1.3-10.6 0.02 
 
1 0.6-1.7 0.9 
 DRC # 0.8 0.3-2.1 0.6 
 
0.9 0.5-1.6 0.78 
 





HR 95% CI p-value** 
 
HR 95% CI p-value** 
 DNA damage# 4.4 1.1-17.3 0.03 
 
0.9 0.5-1.5 0.58 
 DRC # 0.4 0.1-1.5 0.18 
 
0.9 0.5-1.6 0.65 
 
         *Adjusted for age, smoking habits, T stage and therapy 
     **Adjusted for age, smoking habits and therapy 
     # DNA damage and DRC variables were categorized below/upon the median values (reference group: "below") 
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